Masazumi Fujii

Dr. Masazumi Fujii

Fukushima Medical University
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
Masazumi FujiiMasazumi Fujii
Masazumi Fujii
SMSatoshi Maesawa
Satoshi Maesawa
SISumio Ishiai
Sumio Ishiai
KIKenichiro Iwami
Kenichiro Iwami
MFMiyako Futamura
Miyako Futamura
KSKiyoshi Saito
Kiyoshi Saito
The neural basis of language had been considered as a simple model consisting of the Broca's area, the Wernicke's area, and the arcuate fasciculus (AF) connecting the above two cortical areas. However, it has grown to a larger and more complex model based upon recent advancements in neuroscience such as precise imaging studies of aphasic patients, diffusion tensor imaging studies, functional magnetic resonance imaging studies, and electrophysiological studies with cortical and subcortical stimulation during awake surgery. In the present model, language is considered to be processed through two distinct pathways, the dorsal stream and the ventral stream. The core of the dorsal stream is the superior longitudinal fasciculus/AF, which is mainly associated with phonological processing. On the other hand, semantic processing is done mainly with the ventral stream consisting of the inferior fronto-occipital fasciculus and the intratemporal networks. The frontal aslant tract has recently been named the deep frontal tract connecting the supplementary motor area and the Broca's area and it plays an important role in driving and initiating speech. It is necessary for every neurosurgeon to have basic knowledge of the neural basis of language. This knowledge is essential to plan safer surgery and preserve the above neural structures during surgery.

1 May 2018 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
YMYuta Murakami
Yuta Murakami
MIMasahiro Ichikawa
Masahiro Ichikawa
Mudathir BakhitMudathir Bakhit
Mudathir Bakhit
SJShinya Jinguji
Shinya Jinguji
TSTaku Sato
Taku Sato
KSKiyoshi Saito
Kiyoshi Saito

Verified
Journal Article
Open access
PDF file
KNKenichiro Nagai
Kenichiro Nagai
Masazumi FujiiMasazumi Fujii
Masazumi Fujii
Shinobu KitazumeShinobu Kitazume
Shinobu Kitazume
Gliomas are among the most common tumors of the central nervous system and include highly malignant subtypes, such as glioblastoma, which are associated with poor prognosis. Effective treatments are therefore urgently needed. Despite the recent advances in neuroimaging technologies, differentiating gliomas from other brain diseases such as multiple sclerosis remains challenging in some patients, and often requires invasive brain biopsy. Protein tyrosine phosphatase receptor type Z (PTPRZ) is a heavily glycosylated membrane protein that is highly expressed in the central nervous system. Several reports analyzing mouse tumor models suggest that PTPRZ may have potential as a therapeutic target for gliomas. A soluble cleaved form of PTPRZ (sPTPRZ) in the cerebrospinal fluid is markedly upregulated in glioma patients, making it another promising diagnostic biomarker. Intriguingly, PTPRZ is also involved in the process of remyelination in multiple sclerosis. Indeed, lowered PTPRZ glycosylation by deletion of the glycosyltransferase gene leads to reduced astrogliosis and enhanced remyelination in mouse models of demyelination. Here, we review the expression, molecular structure, and biological roles of PTPRZ. We also discuss glioma and demyelinating diseases, as well as the pathological role of PTPRZ and its application as a diagnostic marker and therapeutic target.

4 June 2015 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
NNNaoki Nishio
Naoki Nishio
Yasushi FujimotoYasushi Fujimoto
Yasushi Fujimoto
Masazumi FujiiMasazumi Fujii
Masazumi Fujii
KSKiyoshi Saito
Kiyoshi Saito
MHMariko Hiramatsu
Mariko Hiramatsu
TNTsutomu Nakashima
Tsutomu Nakashima

31 January 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
Masazumi FujiiMasazumi Fujii
Masazumi Fujii
MKMasao Kobayakawa
Masao Kobayakawa
KSKiyoshi Saito
Kiyoshi Saito
AIAkihiro Inano
Akihiro Inano
AMAkio Morita
Akio Morita
OIon behalf of the BeatNF2 Trial Investigators
on behalf of the BeatNF2 Trial Investigators
Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.

10 May 2019 in Surgical Neurology International
Verified
Journal Article
Open access
RHRyo Hiruta
Ryo Hiruta
SJShinya Jinguji
Shinya Jinguji
TSTaku Sato
Taku Sato
YMYuta Murakami
Yuta Murakami
Mudathir BakhitMudathir Bakhit
Mudathir Bakhit
KSKiyoshi Saito
Kiyoshi Saito
Background: Sinking skin flap syndrome or paradoxical brain herniation is an uncommon neurosurgical complication, which usually occurs in the chronic phase after decompressive craniectomy. We report a unique case presenting with these complications immediately after decompressive craniectomy for severe traumatic brain injury. Case Description: A 65-year-old man had a right acute subdural hematoma (SDH), contusion of the right temporal lobe, and diffuse traumatic subarachnoid hemorrhage with midline shift to the left side. He underwent an emergency evacuation of the right SDH with a right decompressive frontotemporal craniectomy. Immediately after the operation, his neurological and computed tomography (CT) findings had improved. However, within 1 h after the surgery, his neurological signs deteriorated. An additional follow-up CT showed a marked midline shift to the left, i.e., paradoxical brain herniation, and his skin flap overlying the decompressive site was markedly sunken. We immediately performed an urgent cranioplasty with the right temporal lobectomy. He responded well to the procedure. We suspected that a cerebrospinal fluid leak had caused this phenomenon. Conclusion: Decompressive craniectomy for severe traumatic brain injury can lead to sinking skin flap syndrome and/or paradoxical brain herniation even in the acute phase. We believe that immediate cranioplasty allows the reversal of such neurosurgical complications.